Sanofi News

Sanofi Signs Deal for Greater China Rights to Aficamten

MT Newswires11:18 ET

Sanofi's Tolebrutinib Receives FDA Breakthrough Therapy Designation for NrSPMS

TipRanksDec 20 06:28 ET

Cytokinetics Says Sanofi Acquiring Rights for Aficamten in Greater China

MT NewswiresDec 20 03:58 ET

Cytokinetics Announces Sanofi's Acquisition Of Aficamten Rights For HCM Treatment In Greater China

BenzingaDec 20 00:55 ET

Express News | Cytokinetics Inc - Eligible for up to $150 Million in Milestone Payments From Sanofi

ReutersDec 20 00:00 ET

Express News | Cytokinetics Announces Sanofi Acquired Rights to Develop and Commercialize Aficamten in Greater China

ReutersDec 20 00:00 ET

Sanofi: Kress Was the CEO of MorphoSys From 2019 Until It Was Acquired by Novartis in 2024

Dow JonesDec 19 12:06 ET

Sanofi: Appointment Is Subject to Ratification at Ordinary Shareholders' Meeting

Dow JonesDec 19 12:04 ET

Sanofi: This Is Effective From Jan. 1

Dow JonesDec 19 12:02 ET

Sanofi: Jean-Paul Kress Will Join Board of Directors

Dow JonesDec 19 12:01 ET

Presse Release: Jean-Paul Kress to Join Sanofi's Board of Directors

SanofiDec 19 00:00 ET

Express News | CA Governor Newsom Proclaimed State Of Emergency To Further Enhance State's Preparedness And Accelerate The Bird Flu Cross-Agency Response Efforts

BenzingaDec 18 14:45 ET

Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases

Analyst UpgradesDec 18 14:29 ET

European Equities Traded in the US as American Depositary Rise in Wednesday Trading

MT NewswiresDec 18 11:12 ET

Express News | CDC Confirms First Severe Case Of H5N1 Bird Flu In U.S. On December 13; Patient Hospitalized With Severe Case Of Avian Influenza A Virus Infection In Louisiana

BenzingaDec 18 11:08 ET

Sanofi (SNY.US) successfully introduced the TL1A monoclonal antibody for the treatment of inflammatory bowel disease in a Phase IIb study with an investment of 1.5 billion dollars.

In October 2023, Sanofi (SNY.US) reached an agreement with Teva for the development and commercialization of the drug, with an upfront payment of 0.5 billion dollars and milestone payments of up to 1 billion dollars.

Zhitong FinanceDec 18 08:18 ET

SNY, TEVA Stocks Jump on Encouraging Data From IBD Drug Study

Zacks Dec 18 07:30 ET

Strength Seen in Sanofi (SNY): Can Its 6.7% Jump Turn Into More Strength?

Zacks Dec 18 05:45 ET

Sanofi and Teva's Duvakitug Meets Primary Endpoints in Phase IIb Trial

Yahoo FinanceDec 18 05:26 ET

Promising Potential: Sanofi's Strong Pipeline and Strategic Market Focus Drive Buy Rating

TipRanksDec 18 00:35 ET · Ratings